Gareth T Jones

List of Publications by Year
in descending order

153 papers	5,723 citations	87888 38 h-index	88630 70 g-index
155 all docs	155 docs citations	155 times ranked	7118 citing authors

#	Article	IF	Citations
1	Global prevalence of ankylosing spondylitis. Rheumatology, 2014, 53, 650-657.	1.9	490
2	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. Arthritis and Rheumatology, 2015, 67, 568-575.	5.6	323
3	Low back pain in schoolchildren: occurrence and characteristics. Pain, 2002, 97, 87-92.	4.2	275
4	Predictors of Low Back Pain in British Schoolchildren: A Population-Based Prospective Cohort Study. Pediatrics, 2003, 111, 822-828.	2.1	239
5	Adverse events in childhood and chronic widespread pain in adult life: Results from the 1958 British Birth Cohort Study. Pain, 2009, 143, 92-96.	4.2	229
6	Active Exercise, Education, and Cognitive Behavioral Therapy for Persistent Disabling Low Back Pain. Spine, 2007, 32, 1578-1585.	2.0	169
7	HLA-DQA1â€“HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
8	Risk of recurrent stillbirth: systematic review and meta-analysis. BMJ, The, 2015, 350, h3080-h3080.	6.0	153
9	Normative data for the Hospital Anxiety and Depression Scale. Quality of Life Research, 2015, 24, 391-398.	3.1	135
10	Epidemiology of back pain in older adults: prevalence and risk factors for back pain onset. Rheumatology, 2011, 50, 1645-1653.	1.9	129
11	The prevalence and management of low back pain across adulthood: Results from a population-based cross-sectional study (the MUSICIAN study). Pain, 2012, 153, 27-32.	4.2	122
12	Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology, 2013, 52, 825-831.	1.9	116
13	Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis. Annals of the Rheumatic Diseases, 2017, 76, 1815-1822.	0.9	116
14	Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15.2 region. Annals of the Rheumatic Diseases, 2013, 72, 427-436.	0.9	112
15	Current Evidence of Antiâ€“Tumor Necrosis Factor Î± Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Metaâ€Analysis Approach of Individual Drugs. Arthritis Care and Research, 2014, 66, 1073-1084.	3.4	98
16	Genetic variation in the beta2-adrenergic receptor but not catecholamine- O -methyltransferase predisposes to chronic pain: Results from the 1958 British Birth Cohort Study. Pain, 2010, 149, 143-151.	4.2	88
17	Are common symptoms in childhood associated with chronic widespread body pain in adulthood?: Results from the 1958 british birth cohort study. Arthritis and Rheumatism, 2007, 56, 1669-1675.	6.7	78
18	Physical activity and emotional problems amongst adolescents. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 765-772.	3.1	74

#	Article	IF	Citations
19	The characterisation and determinants of quality of life in ANCA associated vasculitis. Annals of the Rheumatic Diseases, 2014, 73, 207-211.	0.9	74
20	Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2016, 55, 1786-1790.	1.9	74
21	Predicting the onset of widespread body pain among children. Arthritis and Rheumatism, 2003, 48, 2615-2621.	6.7	72
22	Genetic and environmental influences on non-specific low back pain in children: a twin study. European Spine Journal, 2008, 17, 502-508.	2.2	67
23	Diet, Lifestyle and Chronic Widespread Pain: Results from the 1958 British Birth Cohort Study. Pain Research and Management, 2011, 16, 87-92.	1.8	63
24	Predicting persistent low back pain in schoolchildren: A prospective cohort study. Arthritis and Rheumatism, 2009, 61, 1359-1366.	6.7	62
25	Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology, 2010, 49, 1383-1390.	1.9	61
26	Coâ€Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. Arthritis and Rheumatology, 2017, 69, 2144-2150.	5.6	59
27	Epidemiology of pain. , 2006, , 1199-1214.		59
28	Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, 54, 964-971.	1.9	58
29	Treatment response and drug retention rates in 24 195 biologic-naÃ¯ve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.9	58
30	Predicting persistent disabling low back pain in general practice: a prospective cohort study. British Journal of General Practice, 2006, 56, 334-41.	1.4	54
31	Can large surveys conducted on highly selected populations provide valid information on the epidemiology of common health conditions? An analysis of UK Biobank data on musculoskeletal pain. British Journal of Pain, 2015, 9, 203-212.	1.5	53
32	A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: rheumatoid arthritis. Rheumatology, 2012, 51, 1707-1713.	1.9	50
33	Explaining fatigue in ANCA-associated vasculitis. Rheumatology, 2013, 52, 1680-1685.	1.9	50
34	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49
35	Predicting new onset of widespread pain following a motor vehicle collision. Journal of Rheumatology, 2006, 33, 968-74.	2.0	49
36	Managing low back pain presenting to primary care: Where do we go from here?. Pain, 2006, 122, 219-222.	4.2	48

#	Article	IF	Citations
37	Role of road traffic accidents and other traumatic events in the onset of chronic widespread pain: Results from a populationâ€based prospective study. Arthritis Care and Research, 2011, 63, 696-701.	3.4	46
38	Determining Pathways to Improvements in Fatigue in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2303-2310.	5.6	46
39	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
40	Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). Annals of the Rheumatic Diseases, 2020, 79, 202-208.	0.9	42
41	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5C	1.9	41
42	Occurrence of Raynaud's phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. Arthritis and Rheumatism, 2003, 48, 3518-3521.	6.7	39
43	The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskeletal Disorders, 2015, 16, 347.	1.9	39
44	Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis. Annals of the Rheumatic Diseases, 2018, 77, 1578-1584.	0.9	39
45	The relationship between body mass index across the life course and knee pain in adulthood: results from the 1958 birth cohort study. Rheumatology, 2011, 50, 2251-2256.	1.9	38
46	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2014, 53, 953-956.	1.9	38
47	What Characterizes Persons Who Do Not Report Musculoskeletal Pain? Results from a 4-year Population-based Longitudinal Study (The Epifund Study). Journal of Rheumatology, 2009, 36, 1071-1077.	2.0	35
48	Environmental risk factors in systemic sclerosis. Current Opinion in Rheumatology, 2013, 25, 179-183.	4.3	35
49	The Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk Arthritis Register. Journal of Rheumatology, 2015, 42, 2059-2065.	2.0	35
50	EULAR recommendations for management of fibromyalgia. Annals of the Rheumatic Diseases, 2017, 76, e54-e54.	0.9	33
51	Psychosocial Vulnerability and Early Life Adversity as Risk Factors for Central Sensitivity Syndromes. Current Rheumatology Reviews, 2016, 12, 140-153.	0.8	33
52	Influence of childhood behaviour on the reporting of chronic widespread pain in adulthood: results from the 1958 British Birth Cohort Study. Rheumatology, 2010, 49, 1882-1888.	1.9	32
53	A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: osteoarthritis. Rheumatology, 2012, 51, 2224-2233.	1.9	32
54	Predicting the onset of knee pain: results from a 2-year prospective study of new workers. Annals of the Rheumatic Diseases, 2007, 66, 400-406.	0.9	31

#	Article	IF	Citations
55	Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome: Results from the British Society for Rheumatology Biologics Register. Journal of Rheumatology, 2019, 46, 145-152.	2.0	31
56	The epidemiology of regular opioid use and its association with mortality: Prospective cohort study of 466 486 UK biobank participants. EClinicalMedicine, 2020, 21, 100321.	7.1	29
57	The prevalence of fibromyalgia in axial spondyloarthritis. Rheumatology International, 2020, 40, 1581-1591.	3.0	28
58	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.9	28
59	Does switching anti-TNFÎ± biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach. Seminars in Arthritis and Rheumatism, 2014, 44, 39-46.	3.4	27
60	Establishing the characteristics for patients with chronic Complex Regional Pain Syndrome: the value of the CRPS-UK Registry. British Journal of Pain, 2015, 9, 122-128.	1.5	27
61	Five Potentially Modifiable Factors Predict Poor Quality of Life in Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis. Journal of Rheumatology, 2018, 45, 62-69.	2.0	27
62	Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review. Seminars in Arthritis and Rheumatism, 2015, 45, 238-250.	3.4	26
63	Chronic widespread bodily pain is increased among individuals with history of fracture: findings from UK Biobank. Archives of Osteoporosis, 2016, 11, 1.	2.4	26
64	Disease Severity in Never Smokers, Exâ€Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. Arthritis Care and Research, 2017, 69, 1407-1413.	3.4	26
65	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology, 2018, 57, 1982-1990.	1.9	26
66	Whether the weather influences pain? Results from the EpiFunD study in North West England. Rheumatology, 2010, 49, 1513-1520.	1.9	25
67	Is there an association between preterm birth or low birthweight and chronic widespread pain? Results from the 1958 <scp>B</scp>irth Cohort Study. European Journal of Pain, 2012, 16, 134-139.	2.8	24
68	Predicting response to anti-TNFÎ± therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology, 2020, 59, 2481-2490.	1.9	24
69	Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2019, 58, 811-819.	1.9	21
70	Realâ€World Sixâ€and Twelveâ€Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care and Research, 2022, 74, 1205-1218.	3.4	20
71	Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology, 2014, 53, 2080-2087.	1.9	19
72	Differences in the prevalence of ankylosing spondylitis in primary and secondary care: only one-third of patients are managed in rheumatology. Rheumatology, 2016, 55, 1820-1825.	1.9	18

#	Article	IF	Citations
73	Realâ€world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2067-2075.	2.8	17
74	Does physical trauma lead to an increase in the risk of new onset widespread pain?. Annals of the Rheumatic Diseases, 2006, 65, 391-393.	0.9	16
75	The epidemiology of regional and widespread musculoskeletal pain in rural versus urban settings in those â‰¥55 years. British Journal of Pain, 2015, 9, 86-95.	1.5	16
76	Impact of Smoking in Response to Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Methodologic Considerations for Longitudinal Observational Studies. Arthritis Care and Research, 2020, 72, 591-599.	3.4	14
77	Epidemiology of chronic pain in children and adolescents: a protocol for a systematic review update. BMJ Open, 2021, 11, e043675.	1.9	13
78	Identification and Validation of Clinically Relevant Clusters of Severe Fatigue in Rheumatoid Arthritis. Psychosomatic Medicine, 2017, 79, 1051-1058.	2.0	13
79	Examining Changes in Central and Peripheral Pain as Mediates of Fatigue Improvement: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 922-926.	3.4	12
80	Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. Arthritis Care and Research, 2017, 69, 1878-1886.	3.4	12
81	Investigating generalizability of results from a randomized controlled trial of the management of chronic widespread pain: the MUSICIAN study. Pain, 2017, 158, 96-102.	4.2	12
82	Psychological therapies for chronic widespread pain and fibromyalgia syndrome. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101416.	3.3	12
83	Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology, 2021, 60, 3189-3198.	1.9	12
84	Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. RMD Open, 2020, 6, e001206.	3.8	11
85	Musculoskeletal health--how early does it start?. Rheumatology, 2009, 48, 1181-1182.	1.9	10
86	A systematic review of prognostic factors for distal upper limb pain. British Journal of Pain, 2015, 9, 241-255.	1.5	10
87	The Maintaining Musculoskeletal Health (MAmMOTH) Study: Protocol for a randomised trial of cognitive behavioural therapy versus usual care for the prevention of chronic widespread pain. BMC Musculoskeletal Disorders, 2016, 17, 179.	1.9	10
88	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatology, 2019, 3, 19.	1.6	10
89	Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?. Annals of the Rheumatic Diseases, 2020, 79, 914-919.	0.9	10
90	Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study). Annals of the Rheumatic Diseases, 2021, 80, 903-911.	0.9	10

#	Article	IF	Citations
91	The effect of COVID-19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study. Rheumatology, 2021, 60, SI13-SI24.	1.9	10
92	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology, 2021, 60, 5795-5800.	1.9	10
93	Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology, 2021, 60, 5734-5742.	1.9	9
94	Pain in children â€“ a call for more longitudinal research. Pain, 2011, 152, 2202-2203.	4.2	8
95	The evidence base for managing older persons with low back pain. British Journal of Pain, 2012, 6, 166-169.	1.5	8
96	Fatigue-related brain white matter changes in granulomatosis with polyangiitis. Rheumatology, 2013, 52, 1429-1434.	1.9	8
97	The effect of an internet option and single-sided printing format to increase the response rate to a population-based study: a randomized controlled trial. BMC Medical Research Methodology, 2014, 14, 104.	3.1	8
98	Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS. Rheumatology, 2021, 60, 4158-4165.	1.9	8
99	Onset of neck pain after a motor vehicle accident: a case-control study. Journal of Rheumatology, 2005, 32, 1576-83.	2.0	8
100	Pain reporting in older adults: the influence of cognitive impairment â€“ results from the Cambridge City >75 Cohort study. British Journal of Pain, 2014, 8, 119-124.	1.5	7
101	Impact of discordance between patientâ€™s and evaluatorâ€™s global assessment on treatment outcomes in 14Â868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
102	The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. Rheumatology, 2021, 60, 4121-4129.	1.9	7
103	European bio-naÃ¯ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7
104	Maintained physical activity and physiotherapy in the management of distal upper limb pain â€“ a protocol for a randomised controlled trial (the arm pain trial). BMC Musculoskeletal Disorders, 2014, 15, 71.	1.9	6
105	The re-evaluation of the measurement of pain in population-based epidemiological studies: The SHAMA study. British Journal of Pain, 2015, 9, 134-141.	1.5	6
106	Maintained physical activity and physiotherapy in the management of distal arm pain: a randomised controlled trial. RMD Open, 2019, 5, e000810.	3.8	6
107	What is the incidence of complex regional pain syndrome (CRPS) Type I within four months of a wrist fracture in the adult population? A systematic review. Hand Therapy, 2020, 25, 45-55.	1.4	6
108	Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology, 2020, 59, 3408-3414.	1.9	6

#	Article	IF	Citations
109	Simplified bedside assessment of pulmonary gas exchange in very preterm infants at 36 weeksâ€™ postmenstrual age. Thorax, 2021, 76, 689-695.	5.6	6
110	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology, 2022, 61, e255-e266.	1.9	6
111	Reproducibility of pain manikins: a comparison of paper versus online questionnaires. British Journal of Pain, 2013, 7, 130-137.	1.5	5
112	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 177.	3.5	5
113	Investigating the role of beliefs about emotions, emotional suppression and distress within a pain management programme for fibromyalgia. British Journal of Pain, 2019, 13, 112-120.	1.5	5
114	Smoking does not protect patients with axial spondyloarthritis from attacks of uveitis. Annals of the Rheumatic Diseases, 2019, 78, 1287-1288.	0.9	5
115	Comment on Hendriks et al.: Prognostic factors for poor recovery in acute whiplash patients. Pain 2005;114:408â€“416. Pain, 2005, 119, 247-248.	4.2	4
116	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 1588-1592.	1.9	4
117	Alternative population sampling frames produced important differences in estimates of association: a caseâ€“control study of vasculitis. Journal of Clinical Epidemiology, 2013, 66, 675-680.	5.0	3
118	Trauma and Fibromyalgia â€” Black and White? Or 50 Shades of Grey?. Journal of Rheumatology, 2014, 41, 1732-1733.	2.0	3
119	Cost-utility of maintained physical activity and physiotherapy in the management of distal arm pain: an economic evaluation of data from a randomized controlled trial. Family Practice, 2019, 36, 179-186.	1.9	3
120	The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBRâ€AS registry. Arthritis Care and Research, 2020, , .	3.4	3
121	Driving difficulties in patients with axial spondyloarthritis: Results from the Scotland Registry for Ankylosing Spondylitis. Arthritis Care and Research, 2021, , .	3.4	3
122	The psychological and psychosocial impact of the Pakistan Kashmir earthquake after 8 months: a preliminary evaluation by PACTT. International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists, 2008, 5, 43-46.	0.1	3
123	224.â€ƒThe Natural History of Ankylosing Spondylitis: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i143-i144.	1.9	2
124	Constructs of health belief and disabling distal upper limb pain. Scandinavian Journal of Pain, 2016, 13, 91-97.	1.3	2
125	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. BMC Rheumatology, 2021, 5, 19.	1.6	2
126	Challenges in the management of distal arm pain. Pain Management, 2012, 2, 97-100.	1.5	1

#	Article	IF	Citations
127	OP0262â€…FACTORS ASSOCIATED WITH ACUTE ANTERIOR UVEITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE BSRBR-AS REGISTER DATABASE. , 2019, , .		1
128	Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data. European Journal of Health Economics, 2022, 23, 1357-1369.	2.8	1
129	Enabling work participation for people with musculoskeletal conditions: lessons from work changes imposed by COVID-19: a mixed-method study. BMJ Open, 2022, 12, e057919.	1.9	1
130	Risk factors for the onset of abdominal pain in children: A prospective population based study. Gastroenterology, 2003, 124, A18.	1.3	0
131	230.â€ƒPredictors of Driving Disability in Ankylosing Spondylitis: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i145-i146.	1.9	0
132	225.â€ƒDeterminants of As-Related Fatigue and the Risks of its Persistence: Results from the Scotland and Ireland Registry for Ankylosing Spondylitis. Rheumatology, 2014, 53, i144-i144.	1.9	0
133	SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)099.â€ƒSMOKING EXPOSURE IS ASSOCIATED WITH INCREASED DISEASE SEVERITY IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR ANKYLOSING SPONDYLITIS. Rheumatology, 2017, 56, .	1.9	0
134	Dimension of pain-related quality of life and self-reported mental health in men and women of the European Prospective Investigation into Cancerâ€“Norfolk cohort: a population-based cross-sectional study. British Journal of Pain, 2018, 12, 35-46.	1.5	0
135	O01â€ƒDo patients with axial spondyloarthritis who meet research criteria for fibromyalgia benefit from biologic therapy?. Rheumatology, 2018, 57, .	1.9	0
136	PTU-002â€…Achieving biochemical remission in crohnâ€™s disease with adalimumab therapy utilsing therapeutic drug monitoring. , 2018, , .		0
137	i084â€ƒThe BSRBR-PsA: plans and progress. Rheumatology, 2018, 57, .	1.9	0
138	186â€ƒQuality of life estimation in economic evaluations and healthcare decision making: different approaches, different results. Results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2018, 57, .	1.9	0
139	K2â€ƒImpact of biologic therapy on work in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and meta-analysis. Rheumatology, 2018, 57, .	1.9	0
140	O20â€ƒThe impact of axial spondyloarthritis on work productivity in individuals living in rural areas: results from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology, 2019, 58, .	1.9	0
141	OP0233â€…THE IMPACT OF EXTRA-ARTICULAR MANIFESTATIONS ON THE CHOICE OF TNF INHIBITOR IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN THE BSRBR-AS REGISTER. , 2019, , .		0
142	BRITSpA at five. Rheumatology, 2020, 59, 699-701.	1.9	0
143	P244â€ƒDetermining factors related to poor quality of life in patients with axSpA: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2020, 59, .	1.9	0
144	P246â€ƒPredicting non-response to biologic therapy amongst patients with axSpA: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2020, 59, .	1.9	0

#	Article	IF	Citations
145	P257â€ƒReal-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?. Rheumatology, 2020, 59, .	1.9	0
146	P155â€…88000 faecal calprotectin measurements over 15 years: insights gained from the edinburgh faecal calprotectin register. , 2021, , .		0
147	EpidemiologÃa del dolor. , 2007, , 1231-1246.		0
148	The psychological and psychosocial impact of the Pakistan Kashmir earthquake after 8 months: a preliminary evaluation by PACTT. International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists, 2008, 5, 43-46.	0.1	0
149	Lessons from experiences of accessing healthcare during the pandemic for remobilizing rheumatology services: a national mixed methods study. Rheumatology Advances in Practice, 2022, 6, rkac013.	0.7	0
150	P178â€ƒAdvising workers with distal arm pain to remain active: a secondary analysis of the ARM trial, a multicentre randomised controlled trial. Rheumatology, 2022, 61, .	1.9	0
151	P272â€ƒPregnancy outcomes in women receiving biological therapy for axial spondyloarthritis. Rheumatology, 2022, 61, .	1.9	0
152	P262â€ƒThe occurrence and characteristics of severe pain in patients with axial spondyloarthritis. Rheumatology, 2022, 61, .	1.9	0
153	OA17â€ƒThe risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: data from the BSR registry in axial spondyloarthritis (BSRBR-AS) and meta-analysis. Rheumatology, 2022, 61, .	1.9	0